PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER

前列腺癌、肺癌、结直肠癌和卵巢癌 (PLCO)

• 批准号: 2595068
• 负责人: SAMEER S RAFLA
• 金额: $ 3.54万
• 依托单位: MAIMONIDES MEDICAL CENTER (BROOKLYN)
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-09-30 至 2008-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2595068
• 关键词: biopsy; blood chemistry; cancer prevention; clinical trials; colorectal neoplasms; diagnosis quality /standard; diagnostic tests; digital imaging; early diagnosis; endoscopy; female; gender difference; human mortality; human old age (65+); human subject; lung neoplasms; male; mass screening; neoplasm /cancer diagnosis; ovary neoplasms; prognosis; prostate neoplasms; prostate specific antigen; thoracic radiography; ultrasonography

The Prostate, Lung, Colon-rectum and Ovary Cancer Screening Trial is designed to determine in screenees aged 60-74 years at entry whether: a. In females and males (1) screening with flexible sigmoidoscopy (60 cm sigmoidoscope) can reduce mortality from colo-rectal cancer; and, (2) screening with chest x-ray can reduce mortality from lung cancer. b. In males (1) screening with digital rectal examination plus serum prostate-specific antigen (PSA) can reduce mortality from prostate cancer; c. In females (1) screening with pelvic examination plus CA 125 and transvaginal ultrasound can reduce mortality from ovarian cancer; The secondary objectives are: (1) to assess screening variables other than mortality for each of the interventions including sensitivity, specificity, and positive predictive value; (2) to assess incidence, stage, and survival experience of cancer cases and (3) to investigate the mortality predictive value of biologic and or prognostic characterizations of tumor tissue as intermediate endpoints. This contractor will recruit and randomize to screening or control 15,000 subjects in equal gender balance. Screening will be annual for four years, except that sigmoidoscopy will be done only in the initial and last screen. Subjects will be followed for ten years from entry. A total of 148,000 subjects will be recruited by ten participating Screening Centers. The trial also includes a Data Management and Coordinating Center and a Laboratory for blood assays.

前列腺癌、肺癌、结肠直肠癌和卵巢癌筛查试验正在进行 旨在确定进入时年龄为 60-74 岁的筛选者是否： 一个。 在女性和男性中 (1) 软式乙状结肠镜筛查（60 cm 乙状结肠镜）可以降低结直肠癌的死亡率；并且，(2) 胸部 X 光检查可以降低肺癌死亡率。 b. 在男性中 (1)直肠指检加血清筛查 前列腺特异性抗原（PSA）可以降低前列腺死亡率 癌症; c. 在女性中 (1) 盆腔检查加 CA 125 筛查和 经阴道超声检查可以降低卵巢癌的死亡率； 次要目标是： (1) 评估死亡率以外的筛查变量 每项干预措施包括敏感性、特异性和 阳性预测值； (2) 评估发病率、分期和生存率 癌症病例的经验以及（3）调查死亡率 生物学和/或预后特征的预测价值 肿瘤组织作为中间终点。 该承包商将招募并随机进行筛选或控制 15,000 名受试者性别平等。 每年都会进行一次筛选 四年，除了乙状结肠镜检查仅在最初进行 和最后一个屏幕。 受试者将被跟踪自进入之日起十年。 十家参赛机构将招募总计 148,000 名受试者 筛查中心。 该试验还包括数据管理和 血液检测协调中心和实验室。